LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Home・Akcijų sąrašas・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Uždarymo kaina

4.73 4.19

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.33

Max

4.79

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-10M -7.7M
Pardavimai	-10M 529K
Pelno marža	-1,463.516
Darbuotojai	44
EBITDA	-10M -7.7M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+54.53% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	18M 898M
Ankstesnė atidarymo kaina	0.54
Ankstesnė uždarymo kaina	4.73

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

3.255 / 3.365 Palaikymas ir pasipriešinimas

Arbutus Biopharma Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-09 18:13; UTC

Įsigijimai, susijungimai, perėmimai

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

2026-03-09 17:20; UTC

Svarbiausios naujienos

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

2026-03-09 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

2026-03-10 00:00; UTC

Svarbiausios naujienos

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

2026-03-09 23:52; UTC

Rinkos pokalbiai

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

2026-03-09 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

2026-03-09 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-09 23:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Crude Prices Market Talk on March 9

2026-03-09 23:42; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

2026-03-09 23:08; UTC

Svarbiausios naujienos

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

2026-03-09 23:07; UTC

Svarbiausios naujienos

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

2026-03-09 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue Now Fully Owns Peru's Canariaco Copper Project

2026-03-09 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue Completes Acquisition of Remaining Alta Copper Shares

2026-03-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-09 20:47; UTC

Svarbiausios naujienos

The 24 Hours When Oil Markets Went Wild -- WSJ

2026-03-09 20:33; UTC

Svarbiausios naujienos

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

2026-03-09 20:14; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

2026-03-09 19:33; UTC

Svarbiausios naujienos

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

2026-03-09 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

2026-03-09 19:14; UTC

Rinkos pokalbiai

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

2026-03-09 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026-03-09 18:23; UTC

Rinkos pokalbiai

Svarbiausios naujienos

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

2026-03-09 17:58; UTC

Įsigijimai, susijungimai, perėmimai

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

2026-03-09 17:57; UTC

Įsigijimai, susijungimai, perėmimai

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

2026-03-09 17:41; UTC

Svarbiausios naujienos

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

2026-03-09 17:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

2026-03-09 17:08; UTC

Rinkos pokalbiai

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

2026-03-09 17:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-09 17:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Akcijų palyginimas

Kainos pokytis

Arbutus Biopharma Corp Prognozė

Kainos tikslas

By TipRanks

54.53% į viršų

12 mėnesių prognozė

Vidutinis 7 USD 54.53%

Aukščiausias 7 USD

Žemiausias 7 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arbutus Biopharma Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Arbutus Biopharma Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.255 / 3.365Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.